INVITAE CORP (NVTA)

Invitae files for Chapter 11 bankruptcy to address huge debt load (OTCMKTS:NVTA)

More on Invitae Invitae's High-Stakes Financial Maneuvering: Dilution Might Not Be That Bad Stocks To Watch: Energy Market Drama And Financial Earnings Headline

Genetic Testing Firm Invitae, Backed by SoftBank and Cathie Wood, Files for Chapter 11

Invitae Corp., a genetic-testing company with backers including Softbank Group Corp. and Cathie Wood’s Ark Investment Management, has filed for bankruptcy as the DNA testing industry struggles to regain investor interest following a pandemic-era boom.

The New York Stock Exchange Will Start Delisting Invitae (NVTA) Stock

The New York Stock Exchange has announced that it will begin the process of delisting NVTA stock based on its "abnormally low" price.

Why Is Agrify (AGFY) Stock Up 57% Today?

Agrify stock is rising higher on Tuesday as investors in AGFY celebrate a new milestone for the company with a successful installation.

NVTA Stock: Invitae Plunges 78% on the Brink of Bankruptcy

NVTA stock tumbled yesterday amid a report that the firm could declare bankruptcy soon. The shares were halted for news pending. 

Invitae plunges amid report it may file for bankruptcy within weeks (NYSE:NVTA)

Genetics company Invitae (NVTA) has dropped 70% after reports suggest it has hired restructuring advisers and may be preparing for bankruptcy.

Why Is Invitae (NVTA) Stock Down 75% Today?

Although genetic testing specialist Invitae forwarded a compelling idea, the lack of business substance ultimately cratered NVTA stock.

Monday Sector Laggards: Real Estate, Diagnostics

Invitae stock plunges amid report it may file for bankruptcy within weeks

Genetics company Invitae (NVTA) has dropped 70% after reports suggest it has hired restructuring advisers and may be preparing for bankruptcy.

Invitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare Disease Therapeutics

/PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced a partnership with BridgeBio Pharma, Inc. (Nasdaq: BBIO), a...

Is Invitae Stock a Buy Now?

Invitae shares have lost more than 80% over the past year and a half.

Invitae stock gains on asset sale to Natera (NYSE:NVTA)

Invitae (NVTA) stock gains as company divests certain reproductive health assets to Natera (NTRA) for up to $52.5M upfront and milestone payments. Read more here.

Natera Hits A Nearly Two-Year High After Notching A Win In A Patent Battle

The company must pay $57 million in damages, but that's far less than expected.

Commit To Purchase Invitae At $0.50, Earn 50% Using Options

Invitae Layoffs 2023: What to Know About the Latest NVTA Job Cuts

Invitae layoffs are a hot topic on Friday after the genetics company announced a 15% reduction of its workforce to reduce costs.

Invitae Layoffs 2023: What to Know About the Latest NVTA Job Cuts

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Invitae (NYSE:NVTA) layoffs are coming to the genetics company after announcing...

Invitae divests health tech platform Ciitizen, implements cost saving measures (NYSE:NVTA)

Invitae divests health tech platform Ciitizen, implements cost cuts, and expects annual cash savings of $90-100 million as part of streamlining initiatives.

Invitae Divests Ciitizen Health Data Platform and Implements Further Cost Cuts

/PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced strategic changes to streamline operations and reduce operating cash...

Better Growth Stock: CRISPR Therapeutics vs. Invitae

One of these stocks may be riskier than the other...

Invitae to sell select assets of YouScript to Aranscia (NYSE:NVTA)

Aranscia acquires YouScript from Invitae in an all-cash deal, adding the personalized medication management platform to its portfolio.

Invitae (NVTA) Q3 2023 Earnings Call Transcript

NVTA earnings call for the period ending September 30, 2023.

Invitae Reports Third Quarter 2023 Financial Results

/PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced results for the third quarter ended September 30, 2023....

3 Things About Invitae Every Smart Investor Knows

The last two years have been tumultuous, and there are no calm waters in sight.

Is Invitae Stock a Buy Now?

Invitae shares have dropped more than 60% this year.

3 Penny Stocks That Look Like Intriguing Bets for the Long-Term

Set aside opinions on penny stocks because these three represent companies worth considering as long-term bets.

Landmark Study Reveals Magnitude of Uncertain Results in Clinical Genetic Testing for Hereditary Disease, Points to Evidence-Based Solutions to Reach Definitive Results

/PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced findings from the largest study to date on uncertain results from...

Invitae appoints David Sholehvar as chief operating officer (NYSE:NVTA)

Invitae, a genetic diagnostics company, announced the appointment of David Sholehvar as its new chief operating officer.

Invitae Appoints Dr. David Sholehvar as Chief Operating Officer

/PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced the appointment of veteran healthcare leader David Sholehvar, M.D.,...